Profile: Gentris Corporation
BioHealth Investor Company Directory Profile
GENTRIS CORPORATION
133 Southcenter Court
Suite 400
Morrisville, NC 27560 USA
919.465.0100 Phone
919.465.0554 Fax
Gentris Corporation is transforming global drug development with clinical pharmacogenomic solutions that can accelerate drug development and significantly reduce costs, resulting in more predictable response to drug therapy and less frequent, less severe adverse drug reactions (ADRs).
For every 5,000 drug candidates that enter pre-clinical testing, the Food and Drug Administration will approve only one. As a result, pharmaceutical organizations are under pressure to reduce costs and to address the key reasons for drug failure - ADRs, lack of efficacy and unfavorable pharmacokinetics/drug metabolism properties.
ADRs are currently the fourth leading cause of death and the fifth leading cause of illness in the United States. Gentris helps reduce this statistic with clinical pharmacogenomic testing that will identify patients that may exhibit drug intolerance earlier in the development cycle. With better characterization of patient populations, pharmacogenomics can help reduce drug failure rates by enabling drug companies to modify patients' exposure to drugs based on their drug-response genotype. This can offer the added benefit of making drugs that might otherwise not be approved or withdrawn to become available to patients with compatible pharmacogenomic profiles. Other benefits include shorter and more focused clinical trials that offer the promise of getting drugs to market faster, with higher safety profiles and at lower cost.
Company Mission
Gentris Corporation will lead the new paradigm in healthcare by enabling the administration of medication based on individual genetic variation by offering high quality pharmacogenomic laboratory testing services and diagnostic products
This is a BioHealth Investor company profile. Promote your company, learn how...
____________________
GENTRIS CORPORATION133 Southcenter Court
Suite 400
Morrisville, NC 27560 USA
919.465.0100 Phone
919.465.0554 Fax
Gentris Corporation is transforming global drug development with clinical pharmacogenomic solutions that can accelerate drug development and significantly reduce costs, resulting in more predictable response to drug therapy and less frequent, less severe adverse drug reactions (ADRs).
For every 5,000 drug candidates that enter pre-clinical testing, the Food and Drug Administration will approve only one. As a result, pharmaceutical organizations are under pressure to reduce costs and to address the key reasons for drug failure - ADRs, lack of efficacy and unfavorable pharmacokinetics/drug metabolism properties.
ADRs are currently the fourth leading cause of death and the fifth leading cause of illness in the United States. Gentris helps reduce this statistic with clinical pharmacogenomic testing that will identify patients that may exhibit drug intolerance earlier in the development cycle. With better characterization of patient populations, pharmacogenomics can help reduce drug failure rates by enabling drug companies to modify patients' exposure to drugs based on their drug-response genotype. This can offer the added benefit of making drugs that might otherwise not be approved or withdrawn to become available to patients with compatible pharmacogenomic profiles. Other benefits include shorter and more focused clinical trials that offer the promise of getting drugs to market faster, with higher safety profiles and at lower cost.
Company Mission
Gentris Corporation will lead the new paradigm in healthcare by enabling the administration of medication based on individual genetic variation by offering high quality pharmacogenomic laboratory testing services and diagnostic products
This is a BioHealth Investor company profile. Promote your company, learn how...
____________________
posted by Nico at
12:42 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home